Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This study is a phase 1, intravenous, open-label, single-dose escalation study to evaluate
the safety, tolerability, pharmacokinetics and pharmacodynamics of ACP-501 (recombinant human
Lecithin Cholesterol Acyl Transferase (rhLCAT)) in subjects with coronary artery disease
(CAD). Four cohorts consisting of 4 subjects each will receive one dose of ACP-501. The dose
will be escalated by cohort.